Seneca Nicholas, Zoghbi Sami S, Liow Jeih-San, Kreisl William, Herscovitch Peter, Jenko Kimberly, Gladding Robert L, Taku Andrew, Pike Victor W, Innis Robert B
National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
J Nucl Med. 2009 May;50(5):807-13. doi: 10.2967/jnumed.108.058453. Epub 2009 Apr 16.
P-glycoprotein (P-gp) is a membrane-bound efflux pump that limits the distribution of drugs to several organs of the body. At the blood-brain barrier, P-gp blocks the entry of both loperamide and its metabolite, N-desmethyl-loperamide (N-dLop), and thereby prevents central opiate effects. Animal studies have shown that (11)C-dLop, compared with (11)C-loperamide, is an especially promising radiotracer because it generates negligible radiometabolites that enter the brain. The purposes of this study were to determine whether (11)C-dLop is a substrate for P-gp at the blood-brain barrier in humans and to measure the distribution of radioactivity in the entire body to estimate radiation exposure.
Brain PET scans were acquired in 4 healthy subjects for 90 min and included concurrent measurements of the plasma concentration of unchanged radiotracer. Time-activity data from the whole brain were quantified using a 1-tissue-compartment model to estimate the rate of entry (K(1)) of radiotracer into the brain. Whole-body PET scans were acquired in 8 healthy subjects for 120 min.
For brain imaging, after the injection of (11)C-dLop the concentration of radioactivity in the brain was low (standardized uptake value, approximately 15%) and stable after approximately 20 min. In contrast, uptake of radioactivity in the pituitary was about 50-fold higher than that in the brain. The plasma concentration of (11)C-dLop declined rapidly, but the percentage composition of plasma was unusually stable, with the parent radiotracer constituting 85% of total radioactivity after approximately 5 min. The rate of brain entry was low (K(1) = 0.009 +/- 0.002 mL.cm(-3).min(-1); n = 4). For whole-body imaging, as a measure of radiation exposure to the entire body the effective dose of (11)C-dLop was 7.8 +/- 0.6 muSv/MBq (n = 8).
The low brain uptake of radioactivity is consistent with (11)C-dLop being a substrate for P-gp in humans and confirms that this radiotracer generates negligible quantities of brain-penetrant radiometabolites. In addition, the low rate of K(1) is consistent with P-gp rapidly effluxing substrates while they transit through the lipid bilayer. The radiation exposure of (11)C-dLop is similar to that of many other (11)C-radiotracers. Thus, (11)C-dLop is a promising radiotracer to study the function of P-gp at the blood-brain barrier, at which impaired function would allow increased uptake into the brain.
P-糖蛋白(P-gp)是一种膜结合的外排泵,它限制药物在体内多个器官的分布。在血脑屏障处,P-gp阻止洛哌丁胺及其代谢物N-去甲基洛哌丁胺(N-dLop)进入,从而防止中枢阿片样作用。动物研究表明,与(11)C-洛哌丁胺相比,(11)C-dLop是一种特别有前景的放射性示踪剂,因为它产生的可进入脑内的放射性代谢物可忽略不计。本研究的目的是确定(11)C-dLop在人体血脑屏障处是否为P-gp的底物,并测量全身放射性分布以估计辐射暴露。
对4名健康受试者进行90分钟的脑部PET扫描,同时测量未变化的放射性示踪剂的血浆浓度。使用单组织隔室模型对全脑的时间-活性数据进行定量,以估计放射性示踪剂进入脑内的速率(K(1))。对8名健康受试者进行120分钟的全身PET扫描。
对于脑成像,注射(11)C-dLop后,脑内放射性浓度较低(标准化摄取值约为15%),约20分钟后稳定。相比之下,垂体的放射性摄取比脑内高约50倍。(11)C-dLop的血浆浓度迅速下降,但血浆的百分比组成异常稳定,约5分钟后母体放射性示踪剂占总放射性的85%。脑内进入速率较低(K(1)=0.009±0.002 mL·cm(-3)·min(-1);n = 4)。对于全身成像,作为全身辐射暴露的指标,(11)C-dLop的有效剂量为7.8±0.6 μSv/MBq(n = 8)。
脑内放射性摄取低与(11)C-dLop在人体中是P-gp的底物一致,并证实该放射性示踪剂产生的可穿透脑的放射性代谢物数量可忽略不计。此外,低K(1)速率与P-gp在底物穿过脂质双层时迅速外排底物一致。(11)C-dLop的辐射暴露与许多其他(11)C-放射性示踪剂相似。因此,(11)C-dLop是一种有前景的放射性示踪剂,可用于研究血脑屏障处P-gp的功能,该处功能受损会使脑内摄取增加。